# Sangamo Therapeutics, Inc: overview

SGMOQ · OTC · CIK 1001233 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sgmoq.md) · [Financials](/companies/sgmoq/financials.md) · [Filings](/companies/sgmoq/filings.md) · [Insiders](/companies/sgmoq/insiders.md)

Latest reported revenue: [$1.4m](/filings/0001628280-26-035067.md) for Q1 FY2026, three months to 2026-03-31, from the 10-Q filed May 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-035067).

## Last eight quarters

| Line item | Unit | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0001628280-25-038860.md) | [49.4](/filings/0001001233-25-000024.md) | [7.6 d](/filings/0001628280-26-022029.md) | [6.4](/filings/0001628280-26-035067.md) | [18.3](/filings/0001628280-25-038860.md) | [0.6](/filings/0001001233-25-000024.md) | [14.2 d](/filings/0001628280-26-022029.md) | [1.4](/filings/0001628280-26-035067.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(10416.9%)](/filings/0001628280-25-038860.md) | [21.5%](/filings/0001001233-25-000024.md) | [(344.2%) d](/filings/0001628280-26-022029.md) | [(460.3%)](/filings/0001628280-26-035067.md) | [(97.5%)](/filings/0001628280-25-038860.md) | [(6119.3%)](/filings/0001001233-25-000024.md) | [(268.5%) d](/filings/0001628280-26-022029.md) | [(2215.4%)](/filings/0001628280-26-035067.md) |
| Net margin | % | [(10148.3%)](/filings/0001628280-25-038860.md) | [21.6%](/filings/0001001233-25-000024.md) | [(309.8%) d](/filings/0001628280-26-022029.md) | [(475.3%)](/filings/0001628280-26-035067.md) | [(109.2%)](/filings/0001628280-25-038860.md) | [(6012.0%)](/filings/0001001233-25-000024.md) | [(263.0%) d](/filings/0001628280-26-022029.md) | [(2149.4%)](/filings/0001628280-26-035067.md) |
| Diluted EPS | $ per share | [(0.18)](/filings/0001628280-25-038860.md) | [0.04](/filings/0001001233-25-000024.md) | not reported | [(0.14)](/filings/0001628280-26-035067.md) | [(0.08)](/filings/0001628280-25-038860.md) | [(0.11)](/filings/0001001233-25-000024.md) | not reported | [(0.08)](/filings/0001628280-26-035067.md) |
| Free cash flow | $m | [(26.9) d](/filings/0001628280-25-038860.md) | [11.6 d](/filings/0001001233-25-000024.md) | [(3.5) d](/filings/0001628280-26-022029.md) | [(26.1)](/filings/0001628280-26-035067.md) | [(18.2) d](/filings/0001628280-25-038860.md) | [(28.6) d](/filings/0001001233-25-000024.md) | [(24.4) d](/filings/0001628280-26-022029.md) | [(19.3)](/filings/0001628280-26-035067.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [111](/filings/0001628280-24-010788.md) | [111](/filings/0001628280-24-010788.md) | [176](/filings/0001628280-25-013088.md) | [57.8](/filings/0001628280-26-022029.md) | [39.6](/filings/0001628280-26-022029.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(165.6%)](/filings/0001628280-24-010788.md) | [(180.8%)](/filings/0001628280-24-010788.md) | [(155.5%)](/filings/0001628280-25-013088.md) | [(179.9%)](/filings/0001628280-26-022029.md) | [(306.5%)](/filings/0001628280-26-022029.md) |
| Net margin | % | [(161.1%)](/filings/0001628280-24-010788.md) | [(172.8%)](/filings/0001628280-24-010788.md) | [(146.3%)](/filings/0001628280-25-013088.md) | [(169.4%)](/filings/0001628280-26-022029.md) | [(310.8%)](/filings/0001628280-26-022029.md) |
| Diluted EPS | $ per share | [(1.23)](/filings/0001628280-24-010788.md) | [(1.25)](/filings/0001628280-24-010788.md) | [(1.48)](/filings/0001628280-25-013088.md) | [(0.49)](/filings/0001628280-26-022029.md) | [(0.44)](/filings/0001628280-26-022029.md) |
| Free cash flow | $m | [(257)](/filings/0001628280-24-010788.md) | [(244)](/filings/0001628280-24-010788.md) | [(246)](/filings/0001628280-25-013088.md) | [(67.4)](/filings/0001628280-26-022029.md) | [(97.3)](/filings/0001628280-26-022029.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sgmoq/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2023-09-26 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 6,000,000 | $0.50 | $3.0m | [Form 4](/filings/0000899243-23-019611.md) |
| 2022-08-30 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 100,000 | $5.2652 | $526.5k | [Form 4](/filings/0000899243-22-030136.md) |
| 2022-08-29 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 400,000 | $5.3268 | $2.1m | [Form 4](/filings/0000899243-22-030136.md) |
| 2021-12-28 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 2,764 | $8.5101 | $23.5k | [Form 4](/filings/0000875045-21-000061.md) |
| 2021-12-27 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 600 | $8.56 | $5.1k | [Form 4](/filings/0000875045-21-000060.md) |
| 2021-12-23 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 81,187 | $8.5547 | $694.5k | [Form 4](/filings/0000875045-21-000060.md) |
| 2021-12-09 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 23,660 | $8.5605 | $202.5k | [Form 4](/filings/0000875045-21-000059.md) |
| 2021-12-08 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 75,814 | $8.6373 | $654.8k | [Form 4](/filings/0000875045-21-000058.md) |
| 2021-12-07 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 52,178 | $8.5177 | $444.4k | [Form 4](/filings/0000875045-21-000058.md) |
| 2021-12-02 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 1,874 | $8.5074 | $15.9k | [Form 4](/filings/0000875045-21-000057.md) |
| 2021-12-01 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 730 | $8.5249 | $6.2k | [Form 4](/filings/0000875045-21-000057.md) |
| 2021-11-26 | [Biogen Inc.](/insiders/875045.md) | 10% owner | Sale (S) | 28,884 | $8.6011 | $248.4k | [Form 4](/filings/0000875045-21-000055.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [NOMURA ASSET MANAGEMENT INTERNATIONAL INC.](/funds/921739.md) | 2026-06-30 | $22.0k | 400,000 |  | Unchanged |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $19.7k | 365,600 | Call | Added +47,800 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $13.2k | 244,300 | Put | Added +8,100 |
| [Sandbox Financial Partners, LLC](/funds/1844892.md) | 2026-03-31 | $6.1k | 24,833 |  | Not compared |
| [SIMPLEX TRADING, LLC](/funds/1488542.md) | 2026-06-30 | $4.1k | 76,500 |  | New +76,500 |
| [Axiom Investment Management LLC](/funds/1513703.md) | 2026-06-30 | $1.4k | 25,375 |  | Unchanged |
| [Heritage Investment Group, Inc.](/funds/1876811.md) | 2026-06-30 | $539 | 10,000 |  | New +10,000 |
| [BROWN, LISLE/CUMMINGS, INC.](/funds/14745.md) | 2026-03-31 | $377 | 1,525 |  | Not compared |
| [FLOW TRADERS U.S. LLC](/funds/1466697.md) | 2026-06-30 | $1 | 21,532 |  | Added +34 |
| [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $0 | 1 |  | Unchanged |

## Recent filings

[All 1,185 filings](/companies/sgmoq/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 17:33 ET | [8-K](/filings/0001193125-26-423054.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-423054 |
| 2026-09-21 | 16:01 ET | [8-K](/filings/0001193125-26-396644.md) | 1.03 Bankruptcy or receivership; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001193125-26-396644 |
| 2026-09-08 | 16:06 ET | [8-K](/filings/0001104659-26-105905.md) | 1.03 Bankruptcy or receivership; 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-105905 |
| 2026-08-28 | 16:05 ET | [8-K](/filings/0001193125-26-374328.md) | 1.01 Entry into a material agreement; 1.03 Bankruptcy or receivership; 9.01 Financial statements and exhibits | 0001193125-26-374328 |
| 2026-08-13 | 21:36 ET | [8-K](/filings/0001193125-26-347524.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-347524 |
| 2026-08-12 | 16:02 ET | [8-K](/filings/0001193125-26-346796.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-346796 |
| 2026-07-20 | 16:44 ET | [8-K](/filings/0001193125-26-309012.md) | 1.03 Bankruptcy or receivership; 3.01 Delisting notice | 0001193125-26-309012 |
| 2026-07-01 | 16:01 ET | [8-K](/filings/0001193125-26-292501.md) | 4.01 Change of auditor; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-292501 |
| 2026-06-23 | 16:42 ET | [8-K/A](/filings/0001193125-26-279630.md) | 9.01 Financial statements and exhibits | 0001193125-26-279630 |
| 2026-06-23 | 08:45 ET | [8-K](/filings/0001193125-26-278582.md) | 1.01 Entry into a material agreement; 1.03 Bankruptcy or receivership; 2.03 New direct financial obligation; 2.05 Exit or disposal costs | 0001193125-26-278582 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-022029.md), filed Mar 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1001233
- Tickers: SGMOQ
- Exchange: OTC
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:02 ET. No prices; not investment advice.